Meeting
2023 ASCO Annual Meeting
A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.
Authors
B.J. Rimel
Cedars-Sinai Medical Center, Los Angeles, CA
B.J. Rimel , David Bender , Danielle Enserro , Shannon Neville Westin , Debra L. Richardson , Laura L. Holman , Nitya Alluri , Ashley Stuckey , Ruchi Garg , Sarah Gill , Edward Tanner , Charles A. Leath III, Floor Jenniskens Backes , Aimee Fleury , Helen Mackay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT03660826
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5629)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5629
Abstract #
TPS5629
Poster Bd #
315b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
First Author: Helen Mackay
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
Poster
2023 ASCO Annual Meeting
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
First Author: Alessandro Santin